Abstract:In HIV-1 infection, many antibodies (Abs) are elicited to Envelope (Env) epitopes that are conformationally masked in the native trimer and are only available for antibody recognition after the trimer binds host cell CD4. Among these are epitopes within the Co-Receptor Binding Site (CoRBS) and the constant region 1 and 2 (C1-C2 or cluster A region). In particular, C1-C2 epitopes map to the gp120 face interacting with gp41 in the native, "closed" Env trimer present on HIV-1 virions or expressed on HIV-1-infected cells. Antibodies targeting this region are therefore nonneutralizing and their potential as mediators of antibody-dependent cellular cytotoxicity (ADCC) of HIV-1-infected cells diminished by a lack of available binding targets. Here, we present the design of Ab-CD4 chimeric proteins that consist of the Ab-IgG1 of a CoRBS or cluster A specificity to the extracellular domains 1 and 2 of human CD4. Our Ab-CD4 hybrids induce potent ADCC against infected primary CD4+ T cells and neutralize tier 1 and 2 HIV-1 viruses. Furthermore, competition binding experiments reveal that the observed biological activities rely on both the antibody and CD4 moieties, confirming their cooperativity in triggering conformational rearrangements of Env. Our data indicate the utility of these Ab-CD4 hybrids as antibody therapeutics that are effective in eliminating HIV-1 through the combined mechanisms of neutralization and ADCC. This is also the first report of single-chain-Ab-based molecules capable of opening "closed" Env trimers on HIV-1 particles/infected cells to expose the cluster A region and activate ADCC and neutralization against these nonneutralizing targets. IMPORTANCE Highly conserved epitopes within the coreceptor binding site (CoRBS) and constant region 1 and 2 (C1-C2 or cluster A) are only available for antibody recognition after the HIV-1 Env trimer binds host cell CD4; therefore, they are not accessible on virions and infected cells, where the expression of CD4 is downregulated. Here, we have developed new antibody fusion molecules in which domains 1 and 2 of soluble human CD4 are linked with monoclonal antibodies of either the CoRBS or cluster A specificity. We optimized the conjugation sites and linker lengths to allow each of these novel bispecific fusion molecules to recognize native "closed" Env trimers and induce the structural rearrangements required for exposure of the epitopes for antibody binding. Our in vitro functional testing shows that our Ab-CD4 molecules can efficiently target and eliminate HIV-1-infected cells through antibody-dependent cellular cytotoxicity and inactivate HIV-1 virus through neutralization.

A New Class of Antigen-Specific Killer Cells

Potent antitumour activity of a new class of tumour-specific killer cells

Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

Killing HIV-infected Resting Central Memory CD4+ T Cells by Targeting Inhibitor of Apoptosis Proteins-Inhibited Autophagy

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

Development of a Target Cell-Biologics-effector Cell (TBE) Complex-Based Cell Killing Model to Characterize Target Cell Depletion by T Cell Redirecting Bispecific Agents

TCR-mimic bispecific antibodies to target the HIV-1 reservoir

Development of CD8+ T Cells Expressing Two Distinct Receptors Specific for MTB and HIV‐1 Peptides

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy

One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells

Agonist Antibody That Induces Human Malignant Cells To Kill One Another

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

Nk Cell-Mediated Killing of Target Cells Triggers Robust Antigen-Specific T Cell-Mediated and Humoral Responses

A synthetic cytotoxic T cell platform for rapidly prototyping TCR function

Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells

IgG-Engineered Protective Antigen for Cytosolic Delivery of Proteins into Cancer Cells

Efficient Generation of Antigen-Specific CTLs by the BAFF-activated Human B Lymphocytes As APCs: a Novel Approach for Immunotherapy

Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells

[Construction of Genetically Modified Dendritic Cell Vaccine Expressing Bcr/abl Fusion Gene and Inducing Specific Cytotoxic T Lymphocytes to Kill K562 Cells in Vitro].